Cited by 479Multiple Sclerosis Research StudiesAnimal testing and alternativesPeripheral Neuropathies and Disorders

The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.

How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis.

Steinman, Lawrence, Zamvil, Scott S.·2006·Annals of Neurology

DOI 10.1002/ana.20913

Open this paper in CoChat — free account

Abstract

In their Point of View entitled "Experimental Allergic Encephalomyelitis: A Misleading Model of Multiple Sclerosis," Sriram and Steiner(1) wrote, "The most disappointing aspect of EAE [experimental allergic encephalomyelitis] as a potential model for MS is its almost total inability to point toward a meaningful therapy or therapeutic approach for MS." Actually, EAE has led directly to the development of three therapies approved for use in multiple sclerosis (MS): glatiramer acetate, mitoxantrone, and natalizumab. Several new approaches to MS are in clinical trials based on positive indications in preclinical work relying on EAE. New clues to the pathogenesis of MS and new potential surrogate markers for MS are shown from research involving EAE when it is critically coupled with actual findings in MS. There are pitfalls in overreliance on the EAE model, or on any animal model for any human disease. Nevertheless, over the past 73 years, the EAE model has proved itself remarkably useful for aiding research on MS.

Integrity signals

Registry

Crossref · 10.1002/ana.20913

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdová, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., LUBLIN, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,433
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
Yednock, T. A., Cannon, C., Fritz, L. C., Sánchez‐Madrid, F., Steinman, L., & Karin, N. (1992) · Nature · doi:10.1038/356063a0 · Cited by 1,737
Self-citation
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
Johnson, K., Brooks, B., Cohen, J. A., Ford, C., Goldstein, J., Lisak, R., Myers, L., Panitch, H., Rose, J., Schiffer, R., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,667
Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis
Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E. E., Garren, H., Langer-Gould, A. M., Strober, S., Cannella, B., Allard, J. D., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-500 · Cited by 1,659
Self-citation
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors
Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E. E., Baumruker, T., HIESTAND, P. C., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200176200 · Cited by 1,512
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E. W., LUBLIN, F. D., Weinstock‐Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,342
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
Youssef, S., Stüve, O., Patarroyo, J. C., Ruiz, P. J., Radosevich, J. L., Hur, E. M., Bravo, M., Mitchell, D. J., Sobel, R. A., Steinman, L., et al. (2002) · Nature · doi:10.1038/nature01158 · Cited by 1,096
Self-citation
TNF neutralization in MS
The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) · Neurology · doi:10.1212/wnl.53.3.457 · Cited by 1,068
The T Lymphocyte In Experimental Allergic Encephalomyelitis
Zamvil, S. S., & Steinman, L. (1990) · Annual Review of Immunology · doi:10.1146/annurev.iy.08.040190.003051 · Cited by 1,013
Self-citation

Flagged first, then by citations

Show all 88 references

Sorted by citations

Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
Nanoparticles as Drug Delivery Systems: A Review of the Implication of Nanoparticles’ Physicochemical Properties on Responses in Biological Systems
Yusuf, A., Almotairy, A. R. Z., Henidi, H. A., Alshehri, O. Y., & Aldughaim, M. S. (2023) · Polymers · doi:10.3390/polym15071596 · Cited by 1,008
The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration
Hauser, S. L., & Oksenberg, J. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.011 · Cited by 793
Myelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes‐Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 799
Active induction of experimental allergic encephalomyelitis
Stromnes, I. M., & Goverman, J. M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.285 · Cited by 572
NOX Enzymes in the Central Nervous System: From Signaling to Disease
Sorce, S., & Krause, K. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2578 · Cited by 481
The origin and application of experimental autoimmune encephalomyelitis
Baxter, A. G. (2007) · Nature reviews. Immunology · doi:10.1038/nri2190 · Cited by 458
Type II monocytes modulate T cell–mediated central nervous system autoimmune disease
Weber, M. S., Prod'homme, T., Youssef, S., Dunn, S. E., Rundle, C. D., Lee, L., Patarroyo, J. C., Stüve, O., Sobel, R. A., Steinman, L., et al. (2007) · Nature Medicine · doi:10.1038/nm1620 · Cited by 447
Self-citation
Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system
Friese, M. A., Craner, M. J., Etzensperger, R., Vergo, S. B., Wemmie, J. A., Welsh, M. J., Vincent, A. C., & Fugger, L. H. (2007) · Nature Medicine · doi:10.1038/nm1668 · Cited by 408
CD11b+Ly-6Chi Suppressive Monocytes in Experimental Autoimmune Encephalomyelitis
Zhu, B., Bandô, Y., Xiao, S., Yang, K., Anderson, A. C., Kuchroo, V. K., & Khoury, S. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5228 · Cited by 366
Animal models of Multiple Sclerosis
Procaccini, C., Rosa, V. D., Pucino, V., Formisano, L., & Matarese, G. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.042 · Cited by 403
Animal models of multiple sclerosis: the good, the bad and the bottom line
Ransohoff, R. M. (2012) · Nature Neuroscience · doi:10.1038/nn.3168 · Cited by 379
The genetics of multiple sclerosis: SNPs to pathways to pathogenesis
Oksenberg, J. R., Baranzini, S. E., Sawcer, S., & Hauser, S. L. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2395 · Cited by 347
The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?
Weiner, H. L. (2009) · Annals of Neurology · doi:10.1002/ana.21640 · Cited by 349
B‐cell activation influences T‐cell polarization and outcome of anti‐CD20 B‐cell depletion in central nervous system autoimmunity
Weber, M. S., Prod’homme, T., Patarroyo, J. C., Molnarfi, N., Karnezis, T., Lehmann‐Horn, K., Danilenko, D. M., Eastham‐Anderson, J., Slavin, A., Linington, C., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22081 · Cited by 321
Suppressive Effect of IL-27 on Encephalitogenic Th17 Cells and the Effector Phase of Experimental Autoimmune Encephalomyelitis
Fitzgerald, D. C., Ćirić, B., Touil, T., Harle, H., Grammatikopolou, J., Sarma, J. D., Gran, B., Zhang, G., & Rostami, A. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3268 · Cited by 312
IL ‐33 attenuates EAE by suppressing IL ‐17 and IFN ‐γ production and inducing alternatively activated macrophages
Jiang, H., Milovanović, M., Allan, D., Niedbała, W., Besnard, A., Fukada, S. Y., Alves-Filho, J. C., Togbe, D., Goodyear, C. S., Linington, C., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201141947 · Cited by 319
Activation of the Cholinergic Anti-Inflammatory System by Nicotine Attenuates Neuroinflammation via Suppression of Th1 and Th17 Responses
Nizri, E., Irony-Tur-Sinai, M., Lory, O., Orr‐Urtreger, A., Lavi, E., & Brenner, T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902212 · Cited by 315
The relevance of animal models in multiple sclerosis research
Đenić, A., Johnson, A. J., Bieber, A. J., Warrington, A. E., Rodriguez, M., & Pirko, I. (2010) · Pathophysiology · doi:10.1016/j.pathophys.2010.04.004 · Cited by 312
Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis
Ephrem, A., Chamat, S., Miquel, C., Fisson, S., Mouthon, L., Caligiuri, G., Delignat, S., Elluru, S. R., Bayry, J., Lacroix‐Desmazes, S., et al. (2007) · Blood · doi:10.1182/blood-2007-03-079947 · Cited by 292
Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination
Rostami, A. M., & Ćirić, B. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.03.002 · Cited by 283
The role of antigen presenting cells in multiple sclerosis
Chastain, E. M. L., Duncan, D. S., Rodgers, J. M., & Miller, S. D. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.07.008 · Cited by 271
Neutrophil-related factors as biomarkers in EAE and MS
Rumble, J. M., Huber, A. K., Krishnamoorthy, G., Srinivasan, A., Giles, D. A., Zhang, X., Wang, L., & Segal, B. M. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20141015 · Cited by 262
Interleukin-17 in chronic inflammatory neurological diseases
Milovanovic, J., Arsenijevic, A., Stojanovic, B., Kanjevac, T., Arsenijevic, D., Radosavljevic, G., Milovanovic, M., & Arsenijevic, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00947 · Cited by 250
Natalizumab for Multiple Sclerosis
Ransohoff, R. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmct071462 · Cited by 255
Regulation of Activated CD4+ T Cells by NK Cells via the Qa-1–NKG2A Inhibitory Pathway
Lu, L., Ikizawa, K., Hu, D., Werneck, M. B. F., Wucherpfennig, K. W., & Cantor, H. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.017 · Cited by 253
Is multiple sclerosis a mitochondrial disease?
Mao, P., & Reddy, P. H. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.07.002 · Cited by 246
Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis
Piccio, L. M., Stark, J. L., & Cross, A. H. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0208133 · Cited by 235
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders
Chiu, C., & Chuang, D. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.006 · Cited by 232
Effects of Panax ginseng in Neurodegenerative Diseases
Cho, I. (2012) · Journal of Ginseng Research · doi:10.5142/jgr.2012.36.4.342 · Cited by 225
Passive induction of experimental allergic encephalomyelitis
Stromnes, I. M., & Goverman, J. M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.284 · Cited by 238
Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis
Forte, M. A., Gold, B. G., Marracci, G., Chaudhary, P., Basso, E., Johnsen, D., Yu, X., Fowlkes, J., Rahder, M., Stem, K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702228104 · Cited by 212
Animal models of multiple sclerosis—Potentials and limitations
Mix, E., Meyer-Rienecker, H., Hartung, H., & Zettl, U. K. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.005 · Cited by 224
Lactobacillus reuteri tryptophan metabolism promotes host susceptibility to CNS autoimmunity
Montgomery, T. L., Eckstrom, K. M., Lile, K. H., Caldwell, S. K., Heney, E. R., Lahue, K. G., D’Alessandro, A., Wargo, M. J., & Krementsov, D. N. (2022) · Microbiome · doi:10.1186/s40168-022-01408-7 · Cited by 208
The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets
Hohlfeld, R., Dornmair, K., Meinl, E., & Wekerle, H. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00334-8 · Cited by 205
Galectin-3 Deficiency Reduces the Severity of Experimental Autoimmune Encephalomyelitis
Jiang, H., Rasbi, Z. A., Mensah‐Brown, E. P. K., Shahin, A., Xu, D., Goodyear, C. S., Fukada, S. Y., Liu, F., Liew, F. Y., & Lukić, M. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.2.1167 · Cited by 190
Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins
Brändle, S. M., Obermeier, B., Şenel, M., Bruder, J., Mentele, R., Khademi, M., Olsson, T. P., Tumani, H., Kristoferitsch, W., Lottspeich, F., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522730113 · Cited by 200
The complement cascade: Yin-Yang in neuroinflammation—neuro-protection and -degeneration
Alexander, J. J., Anderson, A. J., Barnum, S. R., Stevens, B., & Tenner, A. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05668.x · Cited by 177
Stage-Specific Role of Interferon-Gamma in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Arellano, G., Ottum, P. A., Reyes, L. I., Burgos, P. I., & Naves, R. F. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00492 · Cited by 178
EAE: imperfect but useful models of multiple sclerosis
Hart, B. A. ‘., Gran, B., & Weissert, R. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.11.006 · Cited by 177
Neuropathic pain behaviours in a chronic-relapsing model of experimental autoimmune encephalomyelitis (EAE)
Olechowski, C. J., Truong, J. J., & Kerr, B. J. (2009) · Pain · doi:10.1016/j.pain.2008.11.002 · Cited by 159
Defining distinct features of anti-MOG antibody associated central nervous system demyelination
Weber, M. S., Derfuss, T. J., Metz, I., & Brück, W. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418762083 · Cited by 164
Initiation and Progression of Axonopathy in Experimental Autoimmune Encephalomyelitis
Soulika, A. M., Lee, E., McCauley, E., Miers, L. A., Bannerman, P. G. C., & Pleasure, D. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.3794-09.2009 · Cited by 161
Environmental factors in autoimmune diseases and their role in multiple sclerosis
Haase, S., Grohme, D. A., Erzler, M., Binsfeld, M., Haghikia, A., Müller, D. N., Linker, R. A., & Kleinewietfeld, M. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2311-1 · Cited by 156
Latency-Associated Peptide Identifies a Novel CD4+CD25+ Regulatory T Cell Subset with TGFβ-Mediated Function and Enhanced Suppression of Experimental Autoimmune Encephalomyelitis
Chen, M., Yan, B., Bandô, Y., Kuchroo, V. K., & Weiner, H. L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7327 · Cited by 146
The Transcription Factor IRF8 Activates Integrin-Mediated TGF-β Signaling and Promotes Neuroinflammation
Yoshida, Y., Yoshimi, R., Yoshii, H., Kim, D., Dey, A., Xiong, H., Munasinghe, J., Yazawa, I., O'Donovan, M. J., Maximova, O. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.11.022 · Cited by 148
Inherited and acquired disorders of myelin: The underlying myelin pathology
Duncan, I. D., & Radcliff, A. B. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.04.002 · Cited by 146
Oestrogen receptor β ligand: a novel treatment to enhance endogenous functional remyelination
Crawford, D. K., Mangiardi, M., Song, B., Patel, R., Du, S., Sofroniew, M. V., Voskuhl, R. R., & Tiwari-Woodruff, S. K. (2010) · Brain · doi:10.1093/brain/awq237 · Cited by 139
Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine
Nizri, E., Irony-Tur-Sinai, M., Faranesh, N., Lavon, I., Lavi, E., Weinstock, M., & Brenner, T. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.06.018 · Cited by 134
Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis
Martinꝉ, R., Sospedra, M., Rosito, M., & Engelhardt, B. (2016) · European Journal of Immunology · doi:10.1002/eji.201646485 · Cited by 133
Multiple sclerosis: molecular pathogenesis and therapeutic intervention
Boutitah-Benyaich, I., Eixarch, H., Villacieros‐Álvarez, J., Hervera, A., Cobo‐Calvo, Á., Montalbán, X., & Espejo, C. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02415-4 · Cited by 149
Current Concepts in Multiple Sclerosis: Autoimmunity Versus Oligodendrogliopathy
Nakahara, J., Maeda, M., Aiso, S., & Suzuki, N. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-011-8287-6 · Cited by 135
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
Piehl, F. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13215 · Cited by 125
Acute Disseminated Encephalomyelitis: Clinical and Pathogenesis Features
Noorbakhsh, F., Johnson, R. T., Emery, D. J., & Power, C. (2008) · Neurologic Clinics · doi:10.1016/j.ncl.2008.03.009 · Cited by 126
Re-Examining the Role of TNF in MS Pathogenesis and Therapy
Fresegna, D., Bullitta, S., Musella, A., Rizzo, F. R., Vito, F. D., Guadalupi, L., Caioli, S., Balletta, S., Sanna, K., Dolcetti, E., et al. (2020) · Cells · doi:10.3390/cells9102290 · Cited by 121
Interactions between host genetics and gut microbiota determine susceptibility to CNS autoimmunity
Montgomery, T. L., Künstner, A., Kennedy, J. J., Fang, Q., Asarian, L., Culp‐Hill, R., D’Alessandro, A., Teuscher, C., Busch, H. S., & Krementsov, D. N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002817117 · Cited by 121
Human Endogenous Retrovirus Protein Activates Innate Immunity and Promotes Experimental Allergic Encephalomyelitis in Mice
Perron, H., Dougier, H.-L., Lomparski, C., Popa, I., Firouzi, R., Bertrand, J., Marušić, S., Portoukalian, J., Jouvin‐Marche, E., VILLIERS, C. L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080128 · Cited by 119
Characterization of relapsing–remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice
Berard, J. L., Wolak, K., Fournier, S., & David, S. (2010) · Glia · doi:10.1002/glia.20935 · Cited by 147
The Contribution of Immune and Glial Cell Types in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Duffy, S. S., Lees, J. G., & Moalem‐Taylor, G. (2014) · Multiple Sclerosis International · doi:10.1155/2014/285245 · Cited by 118
Dual roles of PGE 2 -EP4 signaling in mouse experimental autoimmune encephalomyelitis
Esaki, Y., Li, Y., Sakata, D., Yao, C., Segi‐Nishida, E., Matsuoka, T., Fukuda, K., & Narumiya, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915112107 · Cited by 119
Interferon-β exacerbates Th17-mediated inflammatory disease
Axtell, R. C., Raman, C., & Steinman, L. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.03.008 · Cited by 111
Self-citation
Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges
Lehmann‐Horn, K., Kronsbein, H. C., & Weber, M. S. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612474333 · Cited by 110
Complement in multiple sclerosis: its role in disease and potential as a biomarker
Ingram, G., Hakobyan, S. A., Robertson, N. P., & Morgan, B. P. (2008) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2008.03830.x · Cited by 112
Animal Models of MS Reveal Multiple Roles of Microglia in Disease Pathogenesis
Gao, Z., & Tsirka, S. E. (2011) · Neurology Research International · doi:10.1155/2011/383087 · Cited by 103
The Emerging Role of p38 Mitogen-Activated Protein Kinase in Multiple Sclerosis and Its Models
Krementsov, D. N., Thornton, T. M., Teuscher, C., & Rincón, M. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00688-13 · Cited by 107
Stress and hypothalamic–pituitary–adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosis—A review
Heesen, C., Gold, S. M., Huitinga, I., & Reul, J. M. H. M. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2007.05.002 · Cited by 102
Inhibition of peptidyl-arginine deiminases reverses protein-hypercitrullination and disease in mouse models of multiple sclerosis
Moscarello, M. A., Lei, H., Mastronardi, F. G., Winer, S., Tsui, H., Li, Z., Ackerley, C. A., Zhang, L., Raijmakers, R., & Wood, D. D. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.010520 · Cited by 99
Critical appraisal of animal models of multiple sclerosis
Baker, D., Gerritsen, W. H., Rundle, J., & Amor, S. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511398885 · Cited by 100
Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis
Tan, Y., Abad, C., Lopez, R., Dong, H., Liu, S., Lee, A. W., Gomariz, R. P., Leceta, J., & Waschek, J. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812257106 · Cited by 99
Chronic caffeine treatment attenuates experimental autoimmune encephalomyelitis induced by guinea pig spinal cord homogenates in Wistar rats
Chen, G. Q., Chen, Y., Wang, X. S., Wu, S. Z., Yang, H. M., Xu, H., He, J. C., Wang, X. T., Chen, J., & Zheng, R. Y. (2009) · Brain Research · doi:10.1016/j.brainres.2009.10.054 · Cited by 99
The cannabinoid system and microglia in health and disease
Duffy, S. S., Hayes, J. P., Fiore, N. T., & Moalem‐Taylor, G. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108555 · Cited by 103
Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis
Kalyvas, A., Baskakis, C., Magrioti, V., Constantinou‐Kokotou, V., Stephens, D. L., López‐Vales, R., Lu, J., Yong, V. W., Dennis, E. A., Kokotos, G., et al. (2009) · Brain · doi:10.1093/brain/awp002 · Cited by 97
Behavioral and pathological outcomes in MOG 35–55 experimental autoimmune encephalomyelitis
Jones, M., Nguyen, T. T., DeBoy, C. A., Griffin, J. W., Whartenby, K. A., Kerr, D. A., & Calabresi, P. A. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.05.013 · Cited by 96
Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis
Ge, Z., Da, Y., Xue, Z., Zhang, K., Zhuang, H., Peng, M., Li, Y., Li, W., Simard, A. R., Hao, J., et al. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.12.006 · Cited by 99
Multiple sclerosis therapeutics
Wiendl, H., & Hohlfeld, R. (2009) · Neurology · doi:10.1212/01.wnl.0000344417.42972.54 · Cited by 93
Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?
Mähler, A., Mandel, S. A., Lorenz, M., Rüegg, U. T., Wanker, E. E., Boschmann, M., & Paul, F. (2013) · The EPMA Journal · doi:10.1186/1878-5085-4-5 · Cited by 99
Production of CCL2 by Central Nervous System Cells Regulates Development of Murine Experimental Autoimmune Encephalomyelitis through the Recruitment of TNF- and iNOS-Expressing Macrophages and Myeloid Dendritic Cells
Dogan, R.-N. E., Elhofy, A., & Karpus, W. J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7376 · Cited by 93
Harmful and Protective Effects of Phenolic Compounds from African Medicinal Plants
Mbaveng, A. T., Zhao, Q., & Kuete, V. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-800018-2.00020-0 · Cited by 91
Update on Inflammation, Neurodegeneration, and Immunoregulation in Multiple Sclerosis
Bennett, J. L., & Stüve, O. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181880359 · Cited by 92
Animal models of human disease: Inflammation
Webb, D. R. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.014 · Cited by 91
Animal models of multiple sclerosis for the development and validation of novel therapies – potential and limitations
Mix, E., Meyer-Rienecker, H., & Zettl, U. K. (2008) · Journal of Neurology · doi:10.1007/s00415-008-6003-0 · Cited by 89
Assessing optic nerve pathology with diffusion MRI: from mouse to human
Xu, J., Sun, S., Naismith, R. T., Snyder, A. Z., Cross, A. H., & Song, S. (2008) · NMR in Biomedicine · doi:10.1002/nbm.1307 · Cited by 89
Pharmacological targeting of NLRP3 deubiquitination for treatment of NLRP3-associated inflammatory diseases
Ren, G., Li, J., Zhang, X., Wang, Y., Xiao, Y., Zhang, X., Liu, X., Zhang, W., Ma, W., Zhang, J., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abe2933 · Cited by 88
Therapeutic Effects of Systemic Administration of Chaperone αB-Crystallin Associated with Binding Proinflammatory Plasma Proteins*
Rothbard, J., Kurnellas, M. P., Brownell, S., Adams, C. M., Su, L., Axtell, R., Chen, R., Fathman, C., Robinson, W., & Steinman, L. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.337691 · Cited by 90
Self-citation
The meninges: new therapeutic targets for multiple sclerosis
Russi, A. E., & Brown, M. A. (2014) · Translational research · doi:10.1016/j.trsl.2014.08.005 · Cited by 90
Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications
Ineichen, B. V., Furrer, E., Grüninger, S., Zürrer, W. E., & Macleod, M. R. (2024) · PLoS Biology · doi:10.1371/journal.pbio.3002667 · Cited by 117
Helminth therapy and multiple sclerosis
Fleming, J. O. (2013) · International Journal for Parasitology · doi:10.1016/j.ijpara.2012.10.025 · Cited by 84
Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats
Zhang, Z., Zhang, Z., Wu, Y., & Schluesener, H. J. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.07.013 · Cited by 86
Impacts of Methylxanthines and Adenosine Receptors on Neurodegeneration: Human and Experimental Studies
Chen, J., & Chern, Y. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-13443-2_10 · Cited by 85
Disruption of oligodendrocyte gap junctions in experimental autoimmune encephalomyelitis
Markoullis, K., Sargiannidou, I., Gardner, C., Hadjisavvas, A., Reynolds, R., & Kleopa, K. A. (2012) · Glia · doi:10.1002/glia.22334 · Cited by 83
Korean Red Ginseng and Ginsenoside-Rb1/-Rg1 Alleviate Experimental Autoimmune Encephalomyelitis by Suppressing Th1 and Th17 Cells and Upregulating Regulatory T Cells
Lee, M. J., Jang, M., Choi, J., Chang, B. S., ‍Kim, D. Y., Kim, S., Kwak, Y.-S., Oh, S., Lee, J., Chang, B., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9131-4 · Cited by 83
Optic neuritis in the era of biomarkers
Chen, J. J.-W., Pittock, S. J., Flanagan, E. P., Lennon, V. A., & Bhatti, M. T. (2019) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2019.08.001 · Cited by 83
The good and the bad of neuroinflammation in multiple sclerosis
Naegele, M., & Martinꝉ, R. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52001-2.00003-0 · Cited by 85
MR diffusion changes correlate with ultra-structurally defined axonal degeneration in murine optic nerve
Wu, Q., Butzkueven, H., Gresle, M. M., Kirchhoff, F., Friedhuber, A. M., Yang, Q., Wang, H., Fang, K., Lei, H. C., Egan, G. F., et al. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.06.029 · Cited by 80
Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant
Massey, J. C., Sutton, I. J., Ma, D. D. F., & Moore, J. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00410 · Cited by 81
An overall view of the most common experimental models for multiple sclerosis
Dedoni, S., Scherma, M., Camoglio, C., Siddi, C., Dazzi, L., Puliga, R., Frau, J., Cocco, E., & Fadda, P. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106230 · Cited by 79
Galectin-3: Roles in Neurodevelopment, Neuroinflammation, and Behavior
Srejovic, I. M., Selaković, D., Jovicic, N. U., Jakovljevic, V. L., Lukić, M. L., & Rosic, G. L. (2020) · Biomolecules · doi:10.3390/biom10050798 · Cited by 77
Facets of Theiler’s Murine Encephalomyelitis Virus-Induced Diseases: An Update
Gerhauser, I., Hansmann, F., Ciurkiewicz, M., Löscher, W., & Beineke, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020448 · Cited by 76
CC chemokine receptor 4 is required for experimental autoimmune encephalomyelitis by regulating GM-CSF and IL-23 production in dendritic cells
Poppensieker, K., Otte, D.-M., Schürmann, B., Limmer, A., Dresing, P., Drews, E., Schumak, B., Klotz, L., Raasch, J., Mildner, A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114153109 · Cited by 75

Authors: Steinman, L., & Zamvil, S. S.
Affiliations: Stanford University (US)
University of California, San Francisco (US)
Corresponding author: Steinman, Lawrence
ORCID: Steinman, Lawrence
Zamvil, Scott S.
Venue: Annals of Neurology
Publisher: Wiley
Published: 2006-06-26
Volume: 60
Issue: 1
Pages: 12-21
ISSN: 0364-5134 (ISSN-L)
1531-8249
DOI: 10.1002/ana.20913
OpenAlex: W2140830894
Cited by: 479
References: 88
Citations by year: 2026: 5 · 2025: 6 · 2024: 6 · 2023: 9 · 2022: 23 · 2021: 18 · 2020: 17 · 2019: 17 · 2018: 13 · 2017: 19 · 2016: 22 · 2015: 23 · 2014: 29 · 2013: 44 · 2012: 37
FWCI: 5.49
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Annals of Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: Multiple Sclerosis Society
National Institute of Allergy and Infectious Diseases (R01AI059709)
Topics: Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
Keywords: experimental autoimmune encephalomyelitis, multiple sclerosis, animal models of disease, translational research, glatiramer acetate, mitoxantrone, natalizumab, MS pathogenesis, surrogate markers, preclinical drug development
MeSH terms: Animals, Disease Models, Animal, Encephalomyelitis, Autoimmune, Experimental, Humans, Multiple Sclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks